Journals / Retina-Vitreus / 2012 / Cilt: 20 - Sayı: 3

Vogt-Koyanagi-Harada syndrome: A retrospective case series

Vogt-Koyanagi-Harada sendromu: Retrospektif olgu serisi

Pages
193–198
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Good visual results can be obtained by early recognition and an effective treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To retrospectively evaluate the clinical and imaging features of patients diagnosed and treated as Vogt-Koyanagi-Harada (VKH) syndrome.
📊
Key Findings & Data:Materials and Methods: Medical records of patients treated as VKH syndrome between 2008 and 2012 were evaluated retrospectively.
💡
Conclusion & Impact:Good visual results can be obtained by early recognition and an effective treatment.
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To retrospectively evaluate the clinical and imaging features of patients diagnosed and treated as Vogt-Koyanagi-Harada (VKH) syndrome. Materials and Methods: Medical records of patients treated as VKH syndrome between 2008 and 2012 were evaluated retrospectively. Patients with a follow-up shorter than three months were excluded. Fundus fluoresein angiography (FA), optic coherence tomography (OCT) and if available magnetic resonance imaging features were evaluated. All patients were classified according to the revised diagnostic criteria for VKH Syndrome as “complete”, “incomplete” and “probable”. Results: Twenty-four eyes of 12 patients (seven women and five men) were included. Mean follow-up was 19,2 months (SD: ±17, 4-48 months). The mean age at baseline was 39,6 years (SD:±17.0; 22-65 years). Six patients were classified as complete, five incomplete and one probable. All patients had bilateral involvement and exudative retinal detachment was present. Mean visual acuity at baseline was 4/10 (0,5/10- 10/10). Visual acuity was lower than 6/10 in 17 eyes (%71). All patients except of one were treated with pulse corticosteroids following by oral corticosteroid therapy. Remission was gained with oral corticosteroids in one patient. Additional immunmodulatory therapy was used in five patients. Intravitreal steroid and methotrexate was applied in one resistant case in addition to systemic therapy. Mean visual acuity after therapy increased from 0.4 (±0.39) to 0.84’e (±0.25). Conclusion: VKH syndrome is a rare ocular inflammatory disease in which the etiology is not clear. Because of variable clinical features differential diagnosis can be difficult. Good visual results can be obtained by early recognition and an effective treatment.

Özet

Amaç: Vogt-Koyanagi-Harada (VKH) sendromu tanısıyla kliniğimizde tedavi edilen olguların klinik ve görüntüleme özelliklerinin geriye dönük olarak incelenmesi. Gereç ve Yöntem: Kliniğimizde 2008-2012 yılları arasında izlenmiş olan VKH sendromu olgularının dosya ve görüntü kayıtları retrospektif olarak değerlendirildi. Üç aydan uzun klinik izlemi olan olgular değerlendirilmeye alındı. Ayrıca tüm olguların fundus floresein anjiografi (FA), optik koherens tomografi (OKT) ve mevcutsa manyetik rezonans görüntüleme (MRG) sonuçları kaydedildi. Olgular revize edilmiş uluslararası VKH sendromu sınıflamasına göre “komplet”, “inkomplet ve “muhtemel” olarak sınıflandırıldı. Bulgular: Toplam 12 olgunun (7 kadın/5 erkek) 24 gözü değerlendirilmeye alındı. Ortalama takip süresi 19 aydı (SD:±17 ay, 4-48 ay). Hastaların tanı anındaki ortalama yaşı 39.6 idi (±17.0; 22-65 yıl). Olguların 6’sı muhtemel, 5’i inkomplet ve biri komplet VKH sendromu olarak sınıflandırıldı. Olguların tümünde bilateral tutulum görüldü ve eksüdatif dekolman mevcuttu. Başvuru anında ortalama görme keskinliği 4/10 düzeyindeydi (0.5/10-10/10) ve 17 gözün (%71) görme keskinliği 6/10’dan düşüktü. Bir olgu dışında tüm hastalar pulse steroid ve ardından da oral steroid ile tedavi edildi. Bir olguda sadece oral steroid ile remisyon sağlandı. Beş olguda ilave immunmodülatörler kullanıldı. Bir dirençli olguda sistemik tedaviye ek olarak intravitreal steroid ve metotreksat uygulandı. Tedavi sonrası ortalama görme keskinliği 0.4’ten (±0.39) 0.84’e (±0.25) yükseldi. Tartışma: VKH sendromu ender görülen, etyolojisi kesin olarak aydınlanmamış bir oküler inflamatuar hastalıktır. Klinik görünümü değişken olabilmekle birlikte ayırıcı tanıda zorluklar yaşanabilmektedir. Erken tanı ve etkin bir tedavi ile iyi görsel sonuçlar sağlanabilir.

🔖

Cite This Article

PARLAK, M., DÖNMEZ, O., ÖZBEK, Z. S., YAMAN, A., ÖNER, F. H., SAATÇİ, A. O. (2012). Vogt-Koyanagi-Harada syndrome: A retrospective case series. Retina-Vitreus, Cilt: 20 - Sayı: 3, 193–198. https://ajindex.com/articles/307921

References (19)

  1. Vogt A. Fruhzeitiges Ergaruen der Zilien und Bemerkungen über den sogenanten plötzlichen Eintreitt dieser Veranderung. Klin Monalsbl Augenheilkd 1906;44:228-42
  2. Koyanagi Y. Dysakusis, Alopecia und poliosis bei schwerer uveitis nicht traumatischen ursprugs. Klin Monalsbl Augenheilkd 1929;82:194-211
  3. Harada E. Acute diffuse choroiditis. Acta Soc Ophthalmol Jpn 1926;30:356-78
  4. Bruno MG, McPherson SD. Harada’s disease. Am J Ophthalmol 1949;32:513-22
  5. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995;39:265-92
  6. Mondkar SV, Biswas J, Ganesh SK. Analysis of 87 cases with Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 2000;44:296-301
  7. Yang P, Ren Y, Li B, et al. Clinical characteristics of Vogt-Koyanagi- Harada syndrome in Chinese patients. Ophthalmology 2007;114:606-14
  8. Al Hemidan AI, Tabbara KF, Althomali T. Vogt-Koyanagi-Harada associated with diabetes mellitus and celiac disease in a 3-year-old girl. Eur J Ophthalmol 2006;16:173-77
  9. Read RW, Holland GN, Rao NA et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada Disease: Report of an International Committee on Nomenclature. Am J Ophthalmol 2001;131:647-52
  10. Read RW. Vogt-Koyanagi-Harada disease. Ophthalmol Clin North Am 2002;15:333-41
  11. Wakabayashi T, Morimura Y, Miyamoto Y, et al. Changing patterns of intraocular inflammatory disease in Japan. Ocul Immunol Inflamm 2003;11:277-86
  12. Gouveia EB, Yamamoto JH, Abdalla M, et al. Causas das uveítes em serviço terciário em São Paulo, Brasil. Arq Bras Oftalmol 2004;67:139-45
  13. Yang P, Zhang Z, Zhou H, et al. Clinical patterns and characteristics of uveitis ina tertiary center for uveitis in China. Curr Eye Res 2005;30:943-48
  14. Soheilian M, Heidari K, Yazdani S, et al. Patterns of uveitis in a tertiary eye care center in Iran. Ocul Imm Inflam 2004;12:297-310
  15. Islam SM, Tabbara K. Causes of uveitis at The Eye Center in Saudi Arabia: a retrospective review. Ophthalmic Epidemiology 2002;9:239-49
  16. Tugal-Tutkun I, Ozyazgan Y, Akova YA, et al. The spectrum of Vogt-Koyanagi-Harada disease in Turkey. Int Ophthalmol 2007;27:117-23
  17. Ceylan OM, Uysal Y, Türk A, ve ark. Vogt-Koyanagi-Harada sendromlu olguların klinik özellikleri. T Oft Derg 2010;40:250-54
  18. Sugita S, Takase H, Taguchi C, et al. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci 2006;47:2547-54
  19. Bassili SS, Peyman GA, Gebhar